Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

A Multicenter Prospective Clinical Study of Venetoclax Combined with Azactidine in the Treatment of Newly Diagnosed Acute Leukaemias of Ambiguous Lineage: Interim Analysis of a Phase 2 Trial

Si-Man Huang, Tong-Tong Zhang, Lan Dai, Chao-Ling Wan, Han-Yu Cao, Hai-Ping Dai, Ming-Zhu Xu, Depei Wu, Sheng-Li Xue

Blood (2024) 144 (Supplement 1): 5899.

https://doi.org/10.1182/blood-2024-204660

Published: 2024

Journal Articles

In Vivo HSC Gene Editing for Correction of the Sickle Cell Mutation Using RNA Gene Writers

Lorenzo Tozzi, Giulia Schiroli, Yaser Heshmati, Yu Cao, Michael T. Monte, Apiwat Wangweerawong, James B. Rottman, Rahul Palchaudhuri, Jean-Antoine Ribeil, John Manis, Hari Pujar, William Querbes, Anne Bothmer, Cecilia Cotta-Ramusino, Z. Jane Wang, William E. Salomon, Michael C Holmes

Blood (2024) 144 (Supplement 1): 515.

https://doi.org/10.1182/blood-2024-208626

Published: 2024

Journal Articles

Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

Chao-Ling Wan, Yu-Qing Liu, Fang-Tong Liu, Yuan-Hong Huang, Han-Yu Cao, Si-Man Huang, Kai-Wen Tan, Zihao Wang, Shuai-Shuai Ge, Miao Wang, Haiping Dai, Sheng-Li Xue

Blood (2024) 144 (Supplement 1): 1527.

https://doi.org/10.1182/blood-2024-197933

Published: 2024

Journal Articles

Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study

Fangtong Liu, Chao-Ling Wan, Yu-Qing Liu, Yuan-Hong Huang, Han-Yu Cao, Si-Man Huang, Kai-Wen Tan, Shuai-Shuai Ge, Miao Wang, Mei-Jing Liu, Zihao Wang, Sheng-Li Xue, Haiping Dai

Blood (2024) 144 (Supplement 1): 1484.

https://doi.org/10.1182/blood-2024-202500

Published: 2024

Journal Articles

Delivery of Gene Writers In Vivo to Hematopoietic Stem Cells and T Cells Using Targeted and Untargeted Lipid Nanoparticles (LNP)

Michael T. Monte, Lorenzo Tozzi, Rahul Palchaudhuri, Apiwat Wangweerawong, Yaser Heshmati, Giulia Schiroli, Han Gu, Yu Cao, William E. Salomon, Anne Bothmer, Jason Rodriguez, Mohit Gupta, James B. Rottman, William Querbes, Cecilia Cotta-Ramusino, Michael C Holmes, Hari Pujar, Z. Jane Wang

Blood (2024) 144 (Supplement 1): 2197.

https://doi.org/10.1182/blood-2024-208968

Published: 2024

Journal Articles

Targeted Lipid Nanoparticle Delivery of an RNA Gene Writer In Vivo Enables Generation of CAR-T Cells in a Humanized Mouse Model

Jason Rodriguez, Alberto De Iaco, James B. Rottman, Donghui Liu, Kartika Venugopal, Xin Qiao, Yu Cao, Rebecca Levy, Mohit Gupta, Rahul Palchaudhuri, Bill Querbes, Cecilia Cotta-Ramusino, Hari Pujar, Madhusudan V Peshwa, Michael C Holmes

Blood (2024) 144 (Supplement 1): 4799.

https://doi.org/10.1182/blood-2024-208176

Published: 2024

Journal Articles

Venetoclax Combined with Azacitidine Was Effective and Safe for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma: Preliminary Results of a Phase 2, Multicenter Trial

Han-Yu Cao, Lu-Lu Chen, Chao-Ling Wan, Xiao-Hui Hu, Bing Wu, Li Yang, Li Wang, Yang Zhang, De-Pei Wu, Hai-Ping Dai, Hao Zhang, Shengli Xue

Blood (2023) 142 (Supplement 1): 1501.

https://doi.org/10.1182/blood-2023-179733

Published: 2023

Journal Articles

In Vivo Delivery of RNA By Lipid Nanoparticles (LNP) to Hematopoietic Stem Cells and T Cells in Humanized Mice and Non-Human Primates

Blood (2023) 142 (Supplement 1): 4818.

https://doi.org/10.1182/blood-2023-187271

Published: 2023

Journal Articles

Pharmacokinetics, Safety and Preliminary Efficacy of Multiple Doses of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW117) in Previously Treated Adult and Adolescent Subjects with Severe Hemophilia a: Results from an Open-Label, Multicenter, Phase 2 Study

Feng Xue, Weizhi Chen, Shuxia Guo, Haiying Hua, Yu Cao, Xianqi Feng, Renchi Yang

Blood (2023) 142 (Supplement 1): 2615.

https://doi.org/10.1182/blood-2023-180649

Published: 2023

Journal Articles

Deploying an RNA-Based Gene Writer System and Lipid Nanoparticle (LNP) Delivery to Generate Functional Chimeric Antigen Receptor (CAR) T Cells with in Vitro and In Vivo Anti-Tumor Activity

Michael S Magee, Alberto De Iaco, Jason Rodriguez, James B. Rottman, Donghui Liu, Giulia Schiroli, Pooja Sabhachandani, Yu Cao, Rebecca Levy, Mohit Gupta, Michael T. Monte, Jane Wang, Bill Querbes, Cecilia Cotta-Ramusino, Madhusudan V Peshwa, Michael C Holmes

Blood (2023) 142 (Supplement 1): 2073.

https://doi.org/10.1182/blood-2023-184755

Published: 2023

Journal Articles

RUNX1 Mutation Does Not Significantly Impact the Outcome of Newly Diagnosedadult AML: A Retrospective Study of Chinese AML Patients

Chao-Ling Wan, Yuan-Hong Huang, Si-Man Huang, Tong-Tong Zhang, Kai-Wen Tan, Yan Qiu, Xiang-Dong Shen, Shuai-Shuai Ge, Han-Yu Cao, Yan-Yan Li, Songbai Liu, Qiao-Cheng Qiu, Haiping Dai, Sheng-Li Xue

Blood (2023) 142 (Supplement 1): 4216.

https://doi.org/10.1182/blood-2023-185390

Published: 2023

Journal Articles

Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant

Xing-yu Cao, Jian-Ping Zhang, Yan-Li Zhao, Min Xiong, Jiarui Zhou, Yue Lu, Ruijuan Sun, Zhijie Wei, Deyan Liu, Xian Zhang, Junfang Yang, Peihua Lu

Blood (2022) 140 (Supplement 1): 4802–4803.

https://doi.org/10.1182/blood-2022-166993

Published: 2022

Journal Articles

Immunotherapy with Autologous Anti-CD19 Chimeric Antigen Receptor T Cells Followed By Allogeneic Hematopoietic Stem Cell Transplantation Has Remarkably Improved Leukemia-Free Survival in Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia

Yan-Li Zhao, MD, Tong Wu, MD, De-Yan Liu, Jian-Ping Zhang, Zhi-Jie Wei, Yue Lu, Xing-Yu Cao, Min Xiong, Jia-Rui Zhou, Rui-Juan Sun, Shu-Quan Ji, Chun-Rong Tong, Dao-Pei Lu

Blood (2016) 128 (22): 829.

https://doi.org/10.1182/blood.V128.22.829.829

Published: 2016

Journal Articles

Impact of NCCN Risk Stratification and Minimal Residual Disease on Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Yue Lu, Tong Wu, MD, Yan-Li Zhao, Xing-Yu Cao, De-Yan Liu, Jian-Ping Zhang, Min Xiong, Jia-Rui Zhou, Rui-Juan Sun, Zhi-Jie Wei, Hui Wang, Tong Wang, Hong-Xing Liu, Dao-Pei Lu

Blood (2016) 128 (22): 2296.

https://doi.org/10.1182/blood.V128.22.2296.2296

Published: 2016

Journal Articles

Impact of Cytogenetic and Molecular Markers on Disease-Free Survival of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Yue Lu, Tong Wu, Xing-Yu Cao, Yan-Li Zhao, De-Yan Liu, Min Xiong, Jian-Ping Zhang, Rui-Juan Sun, Zhi-Jie Wei, Jia-Rui Zhou, Hong-Xing Liu, Tong Wang, Shu-Quan Ji, Dao-Pei Lu

Blood (2015) 126 (23): 3217.

https://doi.org/10.1182/blood.V126.23.3217.3217

Published: 2015

Journal Articles

Improved Outcomes of Haploidentical Blood and Marrow Transplantation in Hematologic Malignancies: A Single Center Study of 514 Cases

Yan-Li Zhao, Tong Wu, Yue Lu, Xing-Yu Cao, De-Yan Liu, Min Xiong, Jian-Ping Zhang, Zhi-Jie Wei, Jia-Rui Zhou, Rui-Juan Sun, Chun-Rong Tong, Hong-Xing Liu, Hui Wang, Tong Wang, Shu-Quan Ji, Dao-Pei Lu

Blood (2015) 126 (23): 3224.

https://doi.org/10.1182/blood.V126.23.3224.3224

Published: 2015

Journal Articles

Donor-Derived Ex-Vivo Activated NK Cells in Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Acute Leukemia

Xing-Yu Cao, Tong Wu, Bi-Ping Deng, Rui-Juan Sun, Yue Lu, Yan-Li Zhao, Jian-Ping Zhang, Jia-Rui Zhou, Zhi-Jie Wei, Xiu-Yan Tao, Hui Wang, Hong-Xing Liu, Dao-Pei Lu, Chun-Rong Tong

Blood (2014) 124 (21): 312.

https://doi.org/10.1182/blood.V124.21.312.312

Published: 2014

Journal Articles

Improved Outcomes of Haploidentical Blood and Marrow Transplantation with Giac-3 Protocol That Haploidentical Bone Marrow from the Second Donor As the Third Party Cells

Yan-Li Zhao, Tong Wu, Yue Lu, Xing-Yu Cao, De-Yan Liu, Min Xiong, Zhi-Jie Wei, Jian-Ping Zhang, Jia-Rui Zhou, Rui-Juan Sun, Shu-Quan Ji, Dao-Pei Lu

Blood (2014) 124 (21): 1214.

https://doi.org/10.1182/blood.V124.21.1214.1214

Published: 2014

Journal Articles

Disease-Free Survival Of Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Is Not Associated With Disease Status and Donor Sources

Yue Lu, Tong Wu, Xing-Yu Cao, Yan-Li Zhao, De-Yan Liu, Jia-Rui Zhou, Min Xiong, Jian-Ping Zhang, Rui-Juan Sun, Zhi-Jie Wei, Shu-Quan Ji, Dao-Pei Lu

Blood (2013) 122 (21): 2158.

https://doi.org/10.1182/blood.V122.21.2158.2158

Published: 2013

Journal Articles

Haploidentical Hematopoietic Stem Cell Transplantation of Sex-Matched Donor-Recipient Pair Has Survival Advantage: A Single-Center Study of 440 Cases

Tong Wu, MD, Yan-Li Zhao, MD, Jing-Bo Wang, MD, Xing-Yu Cao, MD, Yu-Ming Yin, MD, Yuan Sun, MD, Yue Lu, MD, Jia-Rui Zhou, MD, Yan-Qun Gao, MD, Wan-Ming Da, MD, Shu-Quan Ji, MD, Yao-Chen Zhang, MD, Dao-Pei Lu, MD

Blood (2010) 116 (21): 228.

https://doi.org/10.1182/blood.V116.21.228.228

Published: 2010

NARROW

A Multicenter Prospective Clinical Study of Venetoclax Combined with Azactidine in the Treatment of Newly Diagnosed Acute Leukaemias of Ambiguous Lineage: Interim Analysis of a Phase 2 Trial

In Vivo HSC Gene Editing for Correction of the Sickle Cell Mutation Using RNA Gene Writers

Venetoclax with Hypomethylating Agents Versus Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Propensity Score Matched Analysis Based on International Consensus Classification

Venetoclax with Hypomethylating Agents Compared with Priming Regimens for Newly Diagnosed Patients with Acute Myeloid Leukemia with Myelodysplasia Related Changes: A Single Center Retrospective Study

Delivery of Gene Writers In Vivo to Hematopoietic Stem Cells and T Cells Using Targeted and Untargeted Lipid Nanoparticles (LNP)

Targeted Lipid Nanoparticle Delivery of an RNA Gene Writer In Vivo Enables Generation of CAR-T Cells in a Humanized Mouse Model

Venetoclax Combined with Azacitidine Was Effective and Safe for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma: Preliminary Results of a Phase 2, Multicenter Trial

In Vivo Delivery of RNA By Lipid Nanoparticles (LNP) to Hematopoietic Stem Cells and T Cells in Humanized Mice and Non-Human Primates

Pharmacokinetics, Safety and Preliminary Efficacy of Multiple Doses of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW117) in Previously Treated Adult and Adolescent Subjects with Severe Hemophilia a: Results from an Open-Label, Multicenter, Phase 2 Study

Deploying an RNA-Based Gene Writer System and Lipid Nanoparticle (LNP) Delivery to Generate Functional Chimeric Antigen Receptor (CAR) T Cells with in Vitro and In Vivo Anti-Tumor Activity

RUNX1 Mutation Does Not Significantly Impact the Outcome of Newly Diagnosedadult AML: A Retrospective Study of Chinese AML Patients

Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant

Immunotherapy with Autologous Anti-CD19 Chimeric Antigen Receptor T Cells Followed By Allogeneic Hematopoietic Stem Cell Transplantation Has Remarkably Improved Leukemia-Free Survival in Refractory/Relapsed B-Cell Acute Lymphoblastic Leukemia

Impact of NCCN Risk Stratification and Minimal Residual Disease on Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Impact of Cytogenetic and Molecular Markers on Disease-Free Survival of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia

Improved Outcomes of Haploidentical Blood and Marrow Transplantation in Hematologic Malignancies: A Single Center Study of 514 Cases

Donor-Derived Ex-Vivo Activated NK Cells in Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in High-Risk Acute Leukemia

Improved Outcomes of Haploidentical Blood and Marrow Transplantation with Giac-3 Protocol That Haploidentical Bone Marrow from the Second Donor As the Third Party Cells

Disease-Free Survival Of Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Is Not Associated With Disease Status and Donor Sources

Haploidentical Hematopoietic Stem Cell Transplantation of Sex-Matched Donor-Recipient Pair Has Survival Advantage: A Single-Center Study of 440 Cases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only